Celltrion Healthcare showcases positive 1year results for novel subcutaneous formulation of infliximab in patients with active Crohns disease and ulcerative colitis presented at The European Crohn's and Colitis Organisation ECCO annual congress

Switching and longterm results from a randomised controlled trial RCT showed that the subcutaneous SC formulation of infliximab was comparable to the intravenous IV formulation of CTP13 biosimilar infliximab in terms of efficacy and safety in patients with...